SCHEMBL19631905

SCHEMBL19631905

COc1ccc(CN(c2cccc(F)n2)S(=O)(=O)c2c(F)cc(N)c(C)c2F)c(OC)c1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.35
MEN1 O00255 3/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
ALDH1A1 P00352 2/20 0.35
HTT P42858 1/20 0.35
TP53 P04637 2/20 0.34
DHFR P00374 1/20 0.34
HDAC8 Q9BY41 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
POLB P06746 2/20 0.32
MAPK1 P28482 2/20 0.32
KDM4E B2RXH2 2/20 0.32
HSP90AB1 P08238 2/20 0.32
TSHR P16473 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
GAA P10253 1/20 0.31
HSP90AA1 P07900 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19631745 0.90 TP53 (0.34) KMT2AMEN1SMN1; SMN2ALDH1A1HTT
SCHEMBL19631743 0.90 KMT2A (0.38) KMT2AMEN1SMN1; SMN2ALDH1A1HTT
SCHEMBL29669086 0.86 KMT2A (0.37) KMT2AMEN1SMN1; SMN2ALDH1A1HTT
SCHEMBL20238565 0.86 KMT2A (0.37) KMT2AMEN1SMN1; SMN2ALDH1A1HTT
SCHEMBL22590218 0.86 KMT2A (0.38) KMT2AMEN1SMN1; SMN2ALDH1A1HTT
SCHEMBL31566459 0.86 KDM4E (0.35) KMT2AMEN1SMN1; SMN2ALDH1A1HTT
SCHEMBL19614107 0.86 DHFR (0.35) KMT2AMEN1SMN1; SMN2ALDH1A1HTT
SCHEMBL31566649 0.85 KMT2A (0.34) KMT2AMEN1SMN1; SMN2ALDH1A1HTT
SCHEMBL31566765 0.84 POLB (0.35) KMT2AMEN1SMN1; SMN2ALDH1A1HTT
SCHEMBL31735293 0.82 MEN1 (0.37) KMT2AMEN1SMN1; SMN2ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-11-12 US disclosed
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-10-27 US disclosed
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2019-04-02 US disclosed
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B KMT2A 2408/4885MEN1 1914/4885SMN1; SMN2 244/4885
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B KMT2A 2408/4885MEN1 1914/4885SMN1; SMN2 244/4885
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B KMT2A 2408/4885MEN1 1914/4885SMN1; SMN2 244/4885
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B KMT2A 2408/4885MEN1 1914/4885SMN1; SMN2 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.